Adherence and Persistence with GLP
Background/Objectives: Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have transformed type 2 diabetes mellitus (T2DM) and obesity care, with clinical trials demonstrating weight loss exceeding 15%. However, real-world effectiveness lags trial efficacy, largely owing to high discontinuation rates. We characterize the global persistence gap and propose a framework integrating Medical ...
Abstract Background/Objectives: Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have transformed type 2 diabetes mellitus (T2DM) and obesity care, with clinical trials demonstrating weight loss exceeding 15%. However, real-world effectiveness lags trial efficacy, largely owing to high discontinuation rates. We characterize the global persistence gap and propose a framework integrating ...
ENDO 2025
Goldman shares insights into the pleiotropic benefits of GLP-1 receptor agonists across cardiovascular, renal, hepatic, and functional domains; offers practical guidance on overcoming clinical and access barriers; and previews investigational incretin therapies that may redefine the standard of care for patients with type 2 diabetes and related ...
The glucagon-like peptide-1 ( GLP-1 ) receptor agonists ( GLP -1RAs) are a class of medications primarily developed for the management of type 2 diabetes (T2D) and are increasingly being used for various other health effects.
Newer Glucagon
The population-level impact of newer glucagon-like peptide-1 receptor agonist ( GLP-1 RA) treatments on patients with type 2 diabetes remains unclear. Therefore, this study investigated the association of newer GLP-1 RAs with population-level diabetes-related outcomes in US adults with type 2 diabetes.
Expanded Indications for GLP-1 Receptor Agonists The 2025 American Diabetes Association (ADA) Standards of Care have broadened the use of GLP-1 receptor agonists beyond glycemic control. These medications are now recommended for patients with type 2 diabetes and chronic kidney disease to reduce cardiovascular risk and protect renal function.
Efficacy and safety of GLP
To compare efficacy and safety of glucagon-like peptide-1 receptor agonists ( GLP -1RAs) in subjects with type 2 diabetes (T2DM).
Aims To assess the level of adherence to glucagon-like peptide-1 receptor agonist ( GLP -1RA) treatment using real-world data and to investigate the sociodemographic and clinical factors associated wi...
Key Details About Updates On Glp 1 Receptor Agonists Improving Adherence In Type 2
GLP-1 receptor agonists were initially developed to treat type 2 diabetes and have had a transformative effect on its therapy, and are highly effective for glycaemic control, with the added benefit of bodyweight reduction and a low risk of causing hypoglycaemia. GLP-1 receptor agonists reduce risks for major adverse cardiovascular events (eg, non-fatal myocardial infarction, stroke, and ...
Introduction Treatment intensification is often required to attain glycemic targets in people living with type 2 diabetes (T2D) but can introduce regimen complexity and increase medication burden. Whether rates of treatment intensification differ by glucose-lowering medication class is unclear. This study investigated comparative treatment durability of glucagon-like peptide-1 receptor ...